Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.32 |
| ▸ | POLRMT | O00411 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20647932 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP2C9KRASBTN3A1POLRMT | |
| SCHEMBL19223302 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP2C9KRASBTN3A1POLRMT | |
| SCHEMBL18636581 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP2C9KRASBTN3A1POLRMT | |
| SCHEMBL18636579 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP2C9KRASBTN3A1POLRMT | |
| SCHEMBL23034636 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP2C9KRASBTN3A1POLRMT | |
| SCHEMBL18636388 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP2C9KRASBTN3A1POLRMT | |
| SCHEMBL23685889 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP2C9KRASBTN3A1POLRMT | |
| SCHEMBL18636609 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP2C9KRASBTN3A1POLRMT | |
| SCHEMBL21283656 | 0.94 | CYP3A4 (0.37) | CYP3A4CYP2C9BTN3A1POLRMT | |
| SCHEMBL22142954 | 0.94 | CYP3A4 (0.37) | CYP3A4CYP2C9BTN3A1POLRMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | EMORY UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-20230255957-A1 | VIRAL ENTRY INHIBITORS AND RNA POLYMERASE INHIBITORS | SELVA THERAPEUTICS, INC. | 2023-08-17 | — | — | US | disclosed |
| US-11266666-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20210283150-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
| US-20210052613-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| US-10251898-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10251904-B2 | Methods for treating arenaviridae and coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-9724360-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2017-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10251904-B2 | Methods for treating arenaviridae and coronaviridae virus infections | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885KRAS 3720/4885 |
| US-20210052613-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | CYP3A4 772/4885CYP2C9 2974/4885KRAS 4427/4885 |
| US-10251898-B2 | Methods for treating Filoviridae virus infections | PNP, PRPF4, RPIA | CYP3A4 772/4885CYP2C9 2974/4885KRAS 4427/4885 |
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | MTAP, PNP, SARS1 | CYP3A4 2707/4885CYP2C9 2638/4885KRAS 2699/4885 |
| US-20210283150-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | ACE2, ACE, PNP | CYP3A4 296/4885CYP2C9 476/4885KRAS 2593/4885 |
| US-20230255957-A1 | VIRAL ENTRY INHIBITORS AND RNA POLYMERASE INHIBITORS | POLRMT, POLR2E, POLR2H | CYP3A4 4037/4885CYP2C9 4780/4885KRAS 2493/4885 |
| US-11266666-B2 | Methods for treating Filoviridae virus infections | PNP, PRPF4, RPIA | CYP3A4 772/4885CYP2C9 2974/4885KRAS 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.